Abbott Laboratories (ABT) operating KPIs
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Worldwide Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,995 | +5.6% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 2,837 | +5.8% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 2,681 | +8.0% | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 2,483 | -6.4% | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 2,654 | +13.5% | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | 2,339 | -17.9% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 2,850 | -2.7% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 2,929 | +1.3% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 2,892 | -1.4% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 2,934 | +5.1% | SEC Filing (0001104659-17-023826) ↗ |
| FY2015 | Dec 31, 2015 | 2,792 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up vascular division (xience des, esprit btk dissolving stent, diamondback 360 atherectomy) — worldwide revenue ($m)
- Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Organic / Comparable Sales Growth (%)5.1% · FY2025
- Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Reported Sales Growth (%)5.6% · FY2025
- Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Foreign Exchange Impact on Sales Growth (%)0.5% · FY2025
- Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — U.S. Revenue ($M)1,118 · FY2025
- Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — International Revenue ($M)1,877 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Worldwide Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-vasc-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.